Pharmaloz Announced Final Contract Negotiations With Major Lozenge Brand; New Partnership Could Add $35M Annually To Revenue By Late 2025, Bringing Total Revenue To $50M With Projected Net Earnings Of $8M-$10M In 2026; Targets $6M Annual Savings...
Pharmaloz Announced Final Contract Negotiations With Major Lozenge Brand; New Partnership Could Add $35M Annually To Revenue By Late 2025, Bringing Total Revenue To $50M With Projected Net Earnings Of $8M-$10M In 2026; Targets $6M Annual Savings...
Pharmaloz宣布与主要糖果品牌进行最终合同谈判；新的合作伙伴关系可能到2025年底每年增加3500万美元的营业收入，使总营业收入达到5000万美元，预计净收益为800万美元。2026年预计达到1000万美元；目标是每年节省600万美元……
Pharmaloz Announced Final Contract Negotiations With Major Lozenge Brand; New Partnership Could Add $35M Annually To Revenue By Late 2025, Bringing Total Revenue To $50M With Projected Net Earnings Of $8M-$10M In 2026; Targets $6M Annual Savings Through Non-Core Operations Cost-Cutting Without Affecting Core Units
Pharmaloz 宣布与主要糖果品牌进行最终合同谈判；新的合作伙伴关系到 2025 年底可能每年增加 3500万美元的营业收入，总营业收入将达到 5000万美元，预计净收益为 800万美元。2026 年的目标为 1000万美元；通过非核心业务的成本削减，目标是每年节省 600万美元，而不会影响核心单元。
The Company will review on Thursday, December 12th, at 12:00 p.m. EST.
公司将于 12 月 12 日星期四中午 12:00 (EST) 进行审查。
GARDEN CITY, NY, Dec. 11, 2024 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ:PRPH) ("ProPhase" or the "Company"), a next-generation biotech, genomics, and diagnostics company, today provided updates on several key initiatives.
纽约花园城，2024 年 12 月 11 日 (全球新闻网络) -- ProPhase Labs, Inc. (纳斯达克:PRPH) ("ProPhase" 或 "公司")，一家下一代生物技术、基因组学和诊断公司，今天就几个关键计划提供了更新。
Securing Low-Interest Rate Financing from a Global Private Equity Fund
从全球股权投资基金获得低利率融资
ProPhase has secured an agreement with a...
ProPhas...
登录免费看全文
登录/注册
热门讨论
美联储暂停降息，你如何调整持仓？
美联储宣布基准利率维持在4.25%—4.50%不变，符合市场预期。你会如何配置资产？
Moo Live
01/30 03:25
联邦公开市场委员会新闻发布会，2025年1月29日